Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTB4R | Q15722 | 4/20 | 0.36 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.32 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.32 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.31 |
| ▸ | CETP | P11597 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26062056 | 0.99 | LTB4R (0.38) | LTB4RCYP4F2CYP4A11MTNR1ACETP | |
| SCHEMBL25997196 | 0.99 | LTB4R (0.38) | LTB4RCYP4F2CYP4A11MTNR1ACETP | |
| SCHEMBL25997177 | 0.99 | LTB4R (0.38) | LTB4RCYP4F2CYP4A11MTNR1ACETP | |
| SCHEMBL26062047 | 0.93 | LTB4R (0.32) | LTB4RCYP4F2CYP4A11 | |
| SCHEMBL25997161 | 0.91 | LTB4R (0.46) | LTB4R | |
| SCHEMBL25997157 | 0.91 | LTB4R (0.38) | LTB4RCYP4F2CYP4A11MTNR1A | |
| SCHEMBL26062049 | 0.90 | LTB4R (0.40) | LTB4R | |
| SCHEMBL26062059 | 0.90 | LTB4R (0.40) | LTB4R | |
| SCHEMBL26062065 | 0.90 | LTB4R (0.47) | LTB4R | |
| SCHEMBL25997188 | 0.90 | LTB4R (0.47) | LTB4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11737995-B2 | Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and derivatives thereof, and their use for the prevention or treatment of disease | ESPERVITA THERAPEUTICS, INC. (US) | 2023-08-29 | — | — | US | disclosed |
| US-11730712-B2 | Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and derivatives thereof, and their use for the prevention or treatment of disease | ESPERVITA THERAPEUTICS, INC. (US) | 2023-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11737995-B2 | Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and derivatives thereof, and their use for the prevention or treatment of disease | AHR, PKD1, CFTR | LTB4R 854/4885CYP4F2 687/4885CYP4A11 605/4885 |
| US-11730712-B2 | Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and derivatives thereof, and their use for the prevention or treatment of disease | CPT1A, PPARG, PC | LTB4R 1119/4885CYP4F2 674/4885CYP4A11 642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.